title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Stocks That Hit 52-Week Lows On Wednesday,20220511T162815,https://www.benzinga.com/markets/options/22/05/27141482/52-weeks-high-and-low-article,GLUE,0.006905,Neutral,0.004193
Stocks That Hit 52-Week Lows On Monday,20220613T161842,https://www.benzinga.com/markets/options/22/06/27677156/52-weeks-high-and-low-article,GLUE,0.005366,Neutral,-0.012266
Stocks That Hit 52-Week Lows On Thursday,20220526T161527,https://www.benzinga.com/markets/options/22/05/27422270/52-weeks-high-and-low-article,GLUE,0.048646,Neutral,0.0087
"Gastroenteropancreatic Neuroendocrine Tumors Market to Showcase a Significant Growth by 2032, Evaluates DelveInsight | Key Players - Eli Lilly and Company, Phanes Therapeutics, Camurus AB, Advanced Accelerator Applications, PharmaMar",20240111T220100,https://www.prnewswire.com/news-releases/gastroenteropancreatic-neuroendocrine-tumors-market-to-showcase-a-significant-growth-by-2032-evaluates-delveinsight--key-players---eli-lilly-and-company-phanes-therapeutics-camurus-ab-advanced-accelerator-applications-pharma-302032286.html,GLUE,0.025139,Neutral,0.05757
53 Biggest Movers From Yesterday,20220330T073305,https://www.benzinga.com/news/22/03/26365918/53-biggest-movers-from-yesterday,GLUE,0.102449,Neutral,-0.003856
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term,20241223T124900,https://www.zacks.com/stock/news/2386694/buy-5-genomics-synthetic-biology-stocks-likely-to-soar-in-short-term,GLUE,0.246582,Neutral,0.055241
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors,20241213T120000,https://www.globenewswire.com/news-release/2024/12/13/2996712/0/en/Monte-Rosa-Therapeutics-Appoints-Dr-Eric-A-Hughes-to-Board-of-Directors.html,GLUE,0.247838,Neutral,-0.044661
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors - Monte Rosa Therapeutics  ( NASDAQ:GLUE ) ,20241213T120000,https://www.benzinga.com/pressreleases/24/12/g42481101/monte-rosa-therapeutics-appoints-dr-eric-a-hughes-to-board-of-directors,GLUE,0.230782,Neutral,-0.040284
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders,20241211T120000,https://www.globenewswire.com/news-release/2024/12/11/2995244/0/en/Monte-Rosa-Therapeutics-Announces-Closing-of-Global-License-Agreement-with-Novartis-to-Advance-T-and-B-Cell-modulating-VAV1-directed-Molecular-Glue-Degraders.html,GLUE,0.077218,Neutral,-0.073016
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer,20241211T120000,https://www.globenewswire.com/news-release/2024/12/11/2995243/0/en/Monte-Rosa-Therapeutics-Presents-Preclinical-Data-at-the-2024-San-Antonio-Breast-Cancer-Symposium-on-the-Potential-of-its-CDK2-directed-Molecular-Glue-Degraders-to-Treat-HR-positiv.html,GLUE,0.136113,Neutral,-0.134279
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors,20241205T120000,https://www.globenewswire.com/news-release/2024/12/05/2992220/0/en/Monte-Rosa-Therapeutics-Provides-Development-Progress-Update-for-Ongoing-MRT-2359-Phase-1-2-Study-in-Patients-with-MYC-driven-Solid-Tumors.html,GLUE,0.094576,Neutral,-0.016255
Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics  ( GLUE ) : Can the Stock Really Move This High?,20241202T224436,https://www.zacks.com/stock/news/2377939/wall-street-analysts-see-a-6409-upside-in-monte-rosa-therapeutics-glue-can-the-stock-really-move-this-high,GLUE,0.285526,Bullish,0.367514
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference,20241126T120000,https://www.globenewswire.com/news-release/2024/11/26/2987333/0/en/Monte-Rosa-Therapeutics-to-Participate-in-the-Piper-Sandler-Healthcare-Conference.html,GLUE,0.263942,Somewhat-Bearish,-0.17475
Wall Street Analysts Think Monte Rosa Therapeutics  ( GLUE )  Could Surge 100.47%: Read This Before Placing a Bet,20241115T145510,https://www.zacks.com/stock/news/2371088/wall-street-analysts-think-monte-rosa-therapeutics-glue-could-surge-10047-read-this-before-placing-a-bet,GLUE,0.284861,Bullish,0.366893
"Monte Rosa Therapeutics  ( GLUE )  Reports Q3 Loss, Tops Revenue Estimates",20241107T133506,https://www.zacks.com/stock/news/2366101/monte-rosa-therapeutics-glue-reports-q3-loss-tops-revenue-estimates,GLUE,0.410059,Somewhat-Bullish,0.221552
Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics  ( GLUE )  is a Great Choice,20241106T170013,https://www.zacks.com/stock/news/2365457/are-you-looking-for-a-top-momentum-pick-why-monte-rosa-therapeutics-glue-is-a-great-choice,GLUE,0.587597,Bullish,0.396767
Wall Street Analysts Believe Monte Rosa Therapeutics  ( GLUE )  Could Rally 67.24%: Here's is How to Trade,20241030T135504,https://www.zacks.com/stock/news/2360696/wall-street-analysts-believe-monte-rosa-therapeutics-glue-could-rally-6724-heres-is-how-to-trade,GLUE,0.2842,Bullish,0.366274
Novartis Ag  ( NVS )  Q3 2024 Earnings Call Transcript,20241029T170011,https://www.fool.com/earnings/call-transcripts/2024/10/29/novartis-ag-nvs-q3-2024-earnings-call-transcript/,GLUE,0.004131,Neutral,0.120363
"PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - PROCEPT BioRobotics  ( NASDAQ:PRCT ) ",20241028T141458,https://www.benzinga.com/news/earnings/24/10/41576730/procept-biorobotics-posts-strong-q3-earnings-joins-monte-rosa-therapeutics-eyepoint-pharmaceuticals,GLUE,0.198221,Somewhat-Bullish,0.205525
"Why Is Monte Rosa Therapeutics Stock Surging On Monday? - Monte Rosa Therapeutics  ( NASDAQ:GLUE ) , Novartis  ( NYSE:NVS ) ",20241028T124631,https://www.benzinga.com/markets/equities/24/10/41573834/why-is-monte-rosa-therapeutics-stock-surging-on-monday,GLUE,0.409503,Somewhat-Bullish,0.246472
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders,20241028T110000,https://www.globenewswire.com/news-release/2024/10/28/2969937/0/en/Monte-Rosa-Therapeutics-Announces-Global-License-Agreement-with-Novartis-to-Advance-T-and-B-Cell-modulating-VAV1-directed-Molecular-Glue-Degraders.html,GLUE,0.085122,Neutral,0.039886
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences,20240828T110000,https://www.globenewswire.com/news-release/2024/08/28/2936883/0/en/Monte-Rosa-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html,GLUE,0.277433,Somewhat-Bearish,-0.192746
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study,20240819T110000,https://www.globenewswire.com/news-release/2024/08/19/2932006/0/en/Monte-Rosa-Therapeutics-Announces-First-Participants-Dosed-in-MRT-6160-Phase-1-Study.html,GLUE,0.098255,Neutral,-0.025002
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study - Monte Rosa Therapeutics  ( NASDAQ:GLUE ) ,20240819T110000,https://www.benzinga.com/pressreleases/24/08/g40436843/monte-rosa-therapeutics-announces-first-participants-dosed-in-mrt-6160-phase-1-study,GLUE,0.18602,Neutral,-0.035323
"Monte Rosa Therapeutics  ( GLUE )  Reports Q2 Loss, Tops Revenue Estimates",20240808T121509,https://www.zacks.com/stock/news/2318897/monte-rosa-therapeutics-glue-reports-q2-loss-tops-revenue-estimates,GLUE,0.406745,Neutral,0.077349
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update,20240808T110000,https://www.globenewswire.com/news-release/2024/08/08/2926748/0/en/Monte-Rosa-Therapeutics-Announces-Second-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html,GLUE,0.039811,Neutral,0.014754
"ADARx Pharmaceuticals Appoints Ajim Tamboli, CFA as Chief Financial Officer",20240730T130500,https://www.benzinga.com/pressreleases/24/07/g40037553/adarx-pharmaceuticals-appoints-ajim-tamboli-cfa-as-chief-financial-officer,GLUE,0.066784,Neutral,0.123294
Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight,20240711T213100,https://www.prnewswire.com/news-releases/molecular-glues-clinical-trial-pipeline-appears-robust-with-10-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-302194515.html,GLUE,0.049784,Neutral,0.104751
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day - Monte Rosa Therapeutics  ( NASDAQ:GLUE ) ,20240708T123657,https://www.benzinga.com/pressreleases/24/07/g39665134/monte-rosa-therapeutics-to-present-at-the-ubs-targeted-protein-degradation-day,GLUE,0.352223,Somewhat-Bearish,-0.254629
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day,20240708T123600,https://www.globenewswire.com/news-release/2024/07/08/2909643/0/en/Monte-Rosa-Therapeutics-to-Present-at-the-UBS-Targeted-Protein-Degradation-Day.html,GLUE,0.407844,Somewhat-Bearish,-0.297543
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis,20240614T124500,https://www.globenewswire.com/news-release/2024/06/14/2898985/0/en/Monte-Rosa-Therapeutics-Presents-Preclinical-Data-at-EULAR-2024-Demonstrating-Therapeutic-Potential-of-MRT-6160-for-the-Treatment-of-Rheumatoid-Arthritis.html,GLUE,0.139265,Neutral,-0.05755
Monte Rosa Therapeutics Announces Leadership Team Promotions - Monte Rosa Therapeutics  ( NASDAQ:GLUE ) ,20240530T110000,https://www.benzinga.com/pressreleases/24/05/g39081952/monte-rosa-therapeutics-announces-leadership-team-promotions,GLUE,0.217346,Neutral,0.017551
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease,20240521T110000,https://www.globenewswire.com/news-release/2024/05/21/2885423/0/en/Monte-Rosa-Therapeutics-Presents-Preclinical-Data-at-Digestive-Disease-Week-2024-Highlighting-Therapeutic-Potential-of-MRT-6160-in-Inflammatory-Bowel-Disease.html,GLUE,0.130358,Neutral,-0.028312
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update - Monte Rosa Therapeutics  ( NASDAQ:GLUE ) ,20240509T110000,https://www.benzinga.com/pressreleases/24/05/g38726371/monte-rosa-therapeutics-announces-first-quarter-2024-financial-results-and-provides-corporate-upda,GLUE,0.069344,Neutral,-0.019207
"Recent Price Trend in Monte Rosa Therapeutics  ( GLUE )  is Your Friend, Here's Why",20240410T125005,https://www.zacks.com/stock/news/2253147/recent-price-trend-in-monte-rosa-therapeutics-glue-is-your-friend-heres-why,GLUE,0.420316,Bullish,0.386716
Does Monte Rosa Therapeutics  ( GLUE )  Have the Potential to Rally 107.79% as Wall Street Analysts Expect?,20240404T135506,https://www.zacks.com/stock/news/2250505/does-monte-rosa-therapeutics-glue-have-the-potential-to-rally-10779-as-wall-street-analysts-expect,GLUE,0.285526,Bullish,0.367514
"Monte Rosa Therapeutics  ( GLUE )  Is a Great Choice for 'Trend' Investors, Here's Why",20240322T125008,https://www.zacks.com/stock/news/2244669/monte-rosa-therapeutics-glue-is-a-great-choice-for-trend-investors-heres-why,GLUE,0.421485,Bullish,0.387385
Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics  ( GLUE ) : Here's What You Should Know,20240319T135505,https://www.zacks.com/stock/news/2242850/wall-street-analysts-predict-an-11791-upside-in-monte-rosa-therapeutics-glue-heres-what-you-should-know,GLUE,0.284861,Somewhat-Bullish,0.304053
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update,20240314T110000,https://www.globenewswire.com/news-release/2024/03/14/2846136/0/en/Monte-Rosa-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html,GLUE,0.070269,Neutral,0.018245
"Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1Î² Pathway Inhibitor",20240311T110000,https://www.globenewswire.com/news-release/2024/03/11/2843611/0/en/Monte-Rosa-Therapeutics-Announces-Initiation-of-IND-Enabling-Studies-for-MRT-8102-A-First-in-Class-NEK7-Directed-Molecular-Glue-Degrader-and-NLRP3-IL-1%CE%B2-Pathway-Inhibitor.html,GLUE,0.096412,Neutral,-0.051695
Why Is Monte Rosa Therapeutics Stock Trading Higher Today? - Monte Rosa Therapeutics  ( NASDAQ:GLUE ) ,20240215T190511,https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37165587/monte-rosa-therapeutics-ai-and-machine-learning-platform-is-adding-significant-valu,GLUE,0.756001,Somewhat-Bearish,-0.182609
"3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street",20240116T140000,https://www.fool.com/investing/2024/01/16/3-incredible-growth-stocks-that-could-soar-in-2024/,GLUE,0.172919,Neutral,0.039127
"Veradigm, Aehr Test Systems, Saratoga Investment And Other Big Stocks Moving Lower On Wednesday - Aehr Test Systems  ( NASDAQ:AEHR ) , Arcadium Lithium  ( NYSE:ALTM ) ",20240110T152708,https://www.benzinga.com/news/24/01/36578224/veradigm-aehr-test-systems-saratoga-investment-and-other-big-stocks-moving-lower-on-wednesday,GLUE,0.209365,Bearish,-0.565018
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024 - Monte Rosa Therapeutics  ( NASDAQ:GLUE ) ,20240108T121500,https://www.benzinga.com/pressreleases/24/01/g36530692/monte-rosa-therapeutics-provides-corporate-update-and-key-anticipated-milestones-for-2024,GLUE,0.151922,Neutral,-0.012067
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024,20240108T121500,https://www.globenewswire.com/news-release/2024/01/08/2805310/0/en/Monte-Rosa-Therapeutics-Provides-Corporate-Update-and-Key-Anticipated-Milestones-for-2024.html,GLUE,0.107303,Neutral,0.005593
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference - Monte Rosa Therapeutics  ( NASDAQ:GLUE ) ,20231121T120000,https://www.benzinga.com/pressreleases/23/11/g35891039/monte-rosa-therapeutics-to-present-at-piper-sandler-healthcare-conference,GLUE,0.271274,Somewhat-Bearish,-0.18937
"Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases",20231107T150000,https://www.globenewswire.com/news-release/2023/11/07/2775281/0/en/Monte-Rosa-Therapeutics-Presents-Preclinical-Data-at-ACR-Convergence-2023-Demonstrating-Potential-of-MRT-6160-a-VAV1-targeted-Molecular-Glue-Degrader-to-Treat-Immunological-and-Inf.html,GLUE,0.136693,Neutral,-0.028977
BD  ( BDX )  Gears Up for Q4 Earnings: What's in the Offing?,20231106T144800,https://www.zacks.com/stock/news/2179234/bd-bdx-gears-up-for-q4-earnings-whats-in-the-offing,GLUE,0.103628,Neutral,0.097676
DaVita  ( DVA )  to Report Q3 Earnings: What's in the Offing?,20231103T172100,https://www.zacks.com/stock/news/2178305/davita-dva-to-report-q3-earnings-whats-in-the-offing,GLUE,0.168099,Neutral,0.124117
DaVita  ( DVA )  to Report Q3 Earnings: What's in the Offing?,20231103T162100,https://www.zacks.com/stock/news/2178305/davita-dva-to-report-q3-earnings-whats-in-the-offing,GLUE,0.168099,Neutral,0.124117
Lantheus  ( LNTH )  to Report Q3 Earnings: What's in the Cards?,20231101T155900,https://www.zacks.com/stock/news/2176580/lantheus-lnth-to-report-q3-earnings-whats-in-the-cards,GLUE,0.158868,Neutral,0.119603
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences,20231027T110000,https://www.globenewswire.com/news-release/2023/10/27/2768275/0/en/Monte-Rosa-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html,GLUE,0.340915,Somewhat-Bearish,-0.20103
"Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules - Monte Rosa Therapeutics  ( NASDAQ:GLUE ) ",20231026T203050,https://www.benzinga.com/pressreleases/23/10/g35451592/monte-rosa-therapeutics-announces-25-million-registered-direct-offering-priced-at-the-market-under,GLUE,0.2256,Neutral,-0.131435
"Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules",20231026T203000,https://www.globenewswire.com/news-release/2023/10/26/2768049/0/en/Monte-Rosa-Therapeutics-Announces-25-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html,GLUE,0.0864,Neutral,-0.083486
"Down -56.34% in 4 Weeks, Here's Why You Should You Buy the Dip in Monte Rosa Therapeutics  ( GLUE ) ",20231024T133506,https://www.zacks.com/stock/news/2170790/down--5634-in-4-weeks-heres-why-you-should-you-buy-the-dip-in-monte-rosa-therapeutics-glue,GLUE,0.493128,Somewhat-Bullish,0.178947
"Crude Oil Moves Lower; Bank of America Profit Beats Expectations - Bank of America  ( NYSE:BAC ) , Assembly Biosciences  ( NASDAQ:ASMB ) ",20231017T183154,https://www.benzinga.com/news/earnings/23/10/35295744/crude-oil-moves-lower-bank-of-america-profit-beats-expectations,GLUE,0.132368,Neutral,0.0
"Dow Surges 100 Points; Goldman Sachs Posts Upbeat Earnings - Evelo Biosciences  ( NASDAQ:EVLO ) , Assembly Biosciences  ( NASDAQ:ASMB ) ",20231017T155630,https://www.benzinga.com/news/earnings/23/10/35292651/dow-surges-100-points-goldman-sachs-posts-upbeat-earnings,GLUE,0.132004,Neutral,0.0
"What's Going On Cancer Player Monte Rosa Therapeutics Stock Today? - Roche Holding  ( OTC:RHHBF ) , Monte Rosa Therapeutics  ( NASDAQ:GLUE ) , Roche Holding  ( OTC:RHHVF ) , Roche Holding  ( OTC:RHHBY ) ",20231017T151351,https://www.benzinga.com/general/biotech/23/10/35288868/whats-going-on-cancer-player-monte-rosa-therapeutics-stock-today,GLUE,0.423251,Somewhat-Bearish,-0.162511
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases,20231017T110000,https://www.globenewswire.com/news-release/2023/10/17/2761334/0/en/Monte-Rosa-Therapeutics-Announces-Strategic-Collaboration-with-Roche-to-Discover-Novel-Molecular-Glue-Degraders-Targeting-Cancer-and-Neurological-Diseases.html,GLUE,0.210884,Neutral,0.100154
Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors,20231017T110000,https://www.globenewswire.com/news-release/2023/10/17/2761331/0/en/Monte-Rosa-Therapeutics-Announces-Interim-PK-PD-and-Clinical-Data-for-MRT-2359-in-Phase-1-2-Trial-for-MYC-Driven-Solid-Tumors.html,GLUE,0.13459,Neutral,0.040992
Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors - Monte Rosa Therapeutics  ( NASDAQ:GLUE ) ,20231017T110000,https://www.benzinga.com/pressreleases/23/10/g35283477/monte-rosa-therapeutics-announces-interim-pkpd-and-clinical-data-for-mrt-2359-in-phase-12-trial-fo,GLUE,0.112709,Neutral,0.039929
Arbor Biotechnologies Appoints Ajim Tamboli as Chief Financial Officer,20230829T110000,https://www.benzinga.com/pressreleases/23/08/g34084969/arbor-biotechnologies-appoints-ajim-tamboli-as-chief-financial-officer,GLUE,0.143415,Neutral,0.133597
Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update,20230810T111500,https://www.globenewswire.com/news-release/2023/08/10/2722527/0/en/Monte-Rosa-Therapeutics-Announces-Second-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html,GLUE,0.069361,Neutral,-0.006123
Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors - Monte Rosa Therapeutics  ( NASDAQ:GLUE ) ,20230726T113000,https://www.benzinga.com/pressreleases/23/07/g33389178/monte-rosa-therapeutics-appoints-dr-anthony-m-manning-to-board-of-directors,GLUE,0.272788,Neutral,0.069074
Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors,20230726T113000,https://www.globenewswire.com/news-release/2023/07/26/2711202/0/en/Monte-Rosa-Therapeutics-Appoints-Dr-Anthony-M-Manning-to-Board-of-Directors.html,GLUE,0.182506,Neutral,-0.029393
Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences,20230530T203000,https://www.globenewswire.com/news-release/2023/05/30/2678856/0/en/Monte-Rosa-Therapeutics-to-Present-at-Upcoming-Investor-and-Industry-Conferences.html,GLUE,0.470894,Neutral,-0.129423
Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update,20230511T113000,https://www.globenewswire.com/news-release/2023/05/11/2666597/0/en/Monte-Rosa-Therapeutics-Announces-First-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html,GLUE,0.074153,Neutral,-0.110401
Monte Rosa Therapeutics Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023,20230417T203000,https://www.globenewswire.com/news-release/2023/04/17/2648480/0/en/Monte-Rosa-Therapeutics-Presents-Preclinical-Data-from-GSPT1-Degrader-Program-Focused-on-MYC-Driven-Cancers-at-AACR-2023.html,GLUE,0.094266,Neutral,-0.132009
Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors - Monte Rosa Therapeutics  ( NASDAQ:GLUE ) ,20230323T113000,https://www.benzinga.com/pressreleases/23/03/g31471796/monte-rosa-therapeutics-appoints-dr-jan-skvarka-to-board-of-directors,GLUE,0.144708,Neutral,0.043301
Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors,20230323T113000,https://www.globenewswire.com/news-release/2023/03/23/2633019/0/en/Monte-Rosa-Therapeutics-Appoints-Dr-Jan-Skvarka-to-Board-of-Directors.html,GLUE,0.143131,Neutral,-0.072305
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update,20230316T113000,https://www.globenewswire.com/news-release/2023/03/16/2628536/0/en/Monte-Rosa-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Corporate-Update.html,GLUE,0.060035,Neutral,-0.081229
Monte Rosa Therapeutics to Present at Upcoming Investor Conferences,20230203T123000,https://www.globenewswire.com/news-release/2023/02/03/2601254/0/en/Monte-Rosa-Therapeutics-to-Present-at-Upcoming-Investor-Conferences.html,GLUE,0.43852,Neutral,-0.065134
Monte Rosa Therapeutics to Present at Upcoming Investor Conferences - Monte Rosa Therapeutics  ( NASDAQ:GLUE ) ,20230203T123000,https://www.benzinga.com/pressreleases/23/02/g30704859/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences,GLUE,0.268294,Neutral,0.054719
How Much Upside is Left in Monte Rosa Therapeutics  ( GLUE ) ? Wall Street Analysts Think 226.46%,20230125T145508,https://www.zacks.com/stock/news/2044092/how-much-upside-is-left-in-monte-rosa-therapeutics-glue-wall-street-analysts-think-22646,GLUE,0.282886,Somewhat-Bullish,0.302462
Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023 - Monte Rosa Therapeutics  ( NASDAQ:GLUE ) ,20230109T123000,https://www.benzinga.com/pressreleases/23/01/g30330274/monte-rosa-therapeutics-outlines-progress-across-portfolio-of-molecular-glue-degraders-and-key-ant,GLUE,0.09402,Neutral,0.005308
Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023,20230109T123000,https://www.globenewswire.com/news-release/2023/01/09/2585095/0/en/Monte-Rosa-Therapeutics-Outlines-Progress-Across-Portfolio-of-Molecular-Glue-Degraders-and-Key-Anticipated-Milestones-for-2023.html,GLUE,0.090931,Neutral,-0.052996
Monte Rosa Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference,20230104T123000,https://www.globenewswire.com/news-release/2023/01/04/2582790/0/en/Monte-Rosa-Therapeutics-to-Present-at-the-41st-Annual-J-P-Morgan-Healthcare-Conference.html,GLUE,0.479683,Somewhat-Bearish,-0.175488
"Dow Surges 150 Points; Crude Oil Falls Sharply - Monte Rosa Therapeutics  ( NASDAQ:GLUE ) , Freight Technologies  ( NASDAQ:FRGT ) ",20221114T193407,https://www.benzinga.com/news/earnings/22/11/29710122/dow-surges-150-points-crude-oil-falls-sharply,GLUE,0.136113,Bullish,0.512915
"Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors - Monte Rosa Therapeutics  ( NASDAQ:GLUE ) ",20221101T113000,https://www.benzinga.com/pressreleases/22/11/g29497407/monte-rosa-therapeutics-announces-first-patient-dosed-in-phase-12-clinical-trial-evaluating-mrt-23,GLUE,0.120733,Neutral,0.007243
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences,20221031T203000,https://www.globenewswire.com/news-release/2022/10/31/2545013/0/en/Monte-Rosa-Therapeutics-Announces-Participation-in-Upcoming-Investor-Conferences.html,GLUE,0.539306,Neutral,-0.149432
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences - Monte Rosa Therapeutics  ( NASDAQ:GLUE ) ,20221031T203000,https://www.benzinga.com/pressreleases/22/10/g29489231/monte-rosa-therapeutics-announces-participation-in-upcoming-investor-conferences,GLUE,0.305058,Neutral,0.1493
Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium,20221020T203000,https://www.globenewswire.com/news-release/2022/10/20/2538856/0/en/Monte-Rosa-Therapeutics-to-Present-at-5th-Annual-Targeted-Protein-Degradation-Summit-and-34th-EORTC-NCI-AACR-Symposium.html,GLUE,0.094266,Neutral,-0.060008
Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium - Monte Rosa Therapeutics  ( NASDAQ:GLUE ) ,20221020T203000,https://www.benzinga.com/pressreleases/22/10/g29350723/monte-rosa-therapeutics-to-present-at-5th-annual-targeted-protein-degradation-summit-and-34th-eort,GLUE,0.107255,Neutral,-0.032569
"5 Value Stocks In The Healthcare Sector - Baudax Bio  ( NASDAQ:BXRX ) , Monte Rosa Therapeutics  ( NASDAQ:GLUE ) , HCA Healthcare  ( NYSE:HCA ) , Lyell Immunopharma  ( NASDAQ:LYEL ) , Aerovate Therapeutics  ( NASDAQ:AVTE ) ",20221017T144630,https://www.benzinga.com/news/22/10/29289923/5-value-stocks-in-the-healthcare-sector,GLUE,0.199037,Somewhat-Bullish,0.286395
"Albertsons Companies, Domino's Pizza And Other Big Gainers From Thursday - Albertsons Companies  ( NYSE:ACI ) , ACM Research  ( NASDAQ:ACMR ) ",20221014T064641,https://www.benzinga.com/news/22/10/29264677/albertsons-companies-dominos-pizza-and-other-big-gainers-from-thursday,GLUE,0.205225,Neutral,0.0
MONTE ROSA CMN STK  ( GLUE )  - Monte Rosa Shares Rise As FDA Announced Clearance To MYC-Driven Cancer Study,20220906T152721,https://www.benzinga.com/general/biotech/22/09/28760545/monte-rosa-shares-rise-as-fda-announced-clearance-to-myc-driven-cancer-study,GLUE,0.44622,Neutral,0.14379
Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results and Business Updates,20220511T113000,https://www.globenewswire.com/news-release/2022/05/11/2440695/0/en/Monte-Rosa-Therapeutics-Reports-First-Quarter-2022-Financial-Results-and-Business-Updates.html,GLUE,0.083589,Neutral,0.017702
Monte Rosa Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates,20220329T113000,https://www.globenewswire.com/news-release/2022/03/29/2411785/0/en/Monte-Rosa-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results-and-Business-Updates.html,GLUE,0.106431,Neutral,0.017554
